Strados Labs Announces Study Evaluating Remote Lung Sound Monitoring to Predict COPD Exacerbations
The SHORE study, in collaboration with Jefferson Health, will assess the feasibility of home-based, continuous monitoring of cough and lung sounds including wheeze and rhonchi following COPD exacerbations. Enrollment started in January.
PHILADELPHIA, PA / ACCESS Newswire / January 28, 2026 / Strados Labs, a medical technology company advancing respiratory care through wearable technologies, today announced an observational research study evaluating remote lung sound monitoring in patients with chronic obstructive pulmonary disease (COPD) using its FDA 510(k) cleared RESP® Biosensor.
The study, titled SL-RS-SHORE (NCT06544928), will take place at Jefferson Einstein Philadelphia Hospital and affiliated outpatient pulmonary clinics. Enrollment began in January, with plans to enroll up to 20 adults with COPD following a recent exacerbation.
COPD exacerbations are a leading cause of hospitalization and readmission in the United States, yet clinicians have limited tools to assess respiratory status once patients return home. While traditional stethoscope auscultation plays a central role in inpatient evaluations, it is largely absent from telehealth and remote monitoring. This study will evaluate whether continuous, passive monitoring of cough and lung sounds using a stethoscope-based wearable device can help extend respiratory assessments into the home environment with the goal of preventing unnecessary readmissions.
